PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hviLink to Publisher's site
 
Hum Vaccin Immunother. 2015 July; 11(7): 1565.
Published online 2015 July 6. doi:  10.1080/21645515.2015.1065123
PMCID: PMC4514200

Letter from the Editor

Dear Reader,

In this issue of Human Vaccines & Immunotherapeutics, we are happy to present a Portrait of Dr. Manon Cox, a lead vaccinologist in developing baculovirus-expressed influenza vaccine (p 1569).

The Immunotherapy section offers a review on oncolytic viruses in cancer treatment (Buijs, p 1573), a preclinical study of mesothelioma vaccine (Hoffmann, p 1585), research papers on optimal cytokine cocktail in DC vaccines (Mei, p 1596) and potential therapeutic target in multiple myeloma (Yousef, p 1606), and a commentary on renal cell carcinoma immunotherapy (Murphy, p 1612).

We are pleased to introduce nine articles on Influenza: estimates of 2014/5 vaccine effectiveness in France (Souty, p 1621), evaluation of disease prevention in a season dominated by a vaccine-matched virus (Martínez-Baz, p 1626), analyses of immune response in patients with post-cancer fatigue (Prinsen, p 1634), parents' sources of vaccine-related information and the link with adolescent uptake (Gargano, p 1641), immunological persistence in individuals >3 years old (Bai, p 1648), immune response to ASO3-adjuvanted A(H1N1) pandemic vaccine in healthcare workers (Lartey, p 1654), post-vaccination B- and T-cell activation in children's tonsils (Panapasa, p 1663), methods for characterization of vaccine content (Tay, p 1674), and a commentary on nutrient limitation in cell-based vaccine production (Liu, p 1686).

Two research papers on HPV include a comparison of immunogenicity and safety of bi- and quadrivalent vaccine administered in two or three doses (Leung, p 1690) and a report on vaccine coverage among adolescents in Georgia, U.S. (Underwood, p 1704). The Hepatitis section presents five research papers on immunological persistence three years after vaccination (Sharma, p 1710), age-dependent antibody decrease and effect of booster doses (Qawasmi, p 1718), age-dependent responses to recombinant hepatitis B (Van Der Meeren, p 1726) and inactivated hepatitis A (Van Der Meeren, p 1730) vaccines, and hyporesponsiveness to vaccination due to insufficient Th activation (Li, p 1736).

The Licensed Vaccines section contains a review on implementing Tdap vaccine for adults (Suryadevara, p 1745), comparison of two WHO-prequalified rabies vaccines (Narayana, p 1749), a report on serological responses in vaccinated and unvaccinated mumps cases during an outbreak (Kaaijk, p 1755), a study of the role of plasmacytoid dendritic cells in adaptive immune response against measles virus (García-León, p 1763), evaluation of new prefilled syringe with reduced-antigen-content dTpa booster vaccine (Pavia-Ruz, p 1772), a meeting report from the 3rd ESCMID conference on vaccines (Esposito, p 1777), and a commentary on measles vaccination in Chinese big cities (Li, p 1779).

We introduce three research papers on Novel Vaccines, namely, on strong protection in mice elicited by a novel ricin vaccine (Zhang, p 1781), on the spread of CMV in the U.S. studied by a dynamic transmission model for application to a vaccine (Hogea, p 1790), and on the design and immunization route of adenovirus-vectored tuberculosis vaccine (Zhang, p 1808).

In addition to a review on Safety assessment of adjuvanted vaccines (Tavares, p 1819), we present three articles on Pneumococcal vaccines: a commentary on the CAPiTA community-acquired pneumonia immunization trial in adults (Isturiz, p 1830), a comparison of adverse events in infants induced by PCV-13 and PCV-7 (Littlejohn, p 1833), and a report on passive immunization of mice by vaccine-induced human antibodies (Brookes, p 1841).

Research articles examine how Public Health administrative data can be used to assess infant immunization status (Kwong, p 1845), intussusception following Rotavirus vaccination in Spain (Pérez-Vilar, p 1853), the impact of formulation and particle size on oil-in-water emulsion adjuvants (Iyer, p 1858), improving the use of RT-qPCR in quantification of yellow fever virus (Fernandes-Monteiro, p 1868), and factors associated with pain and swelling of injection site after Meningococcalvaccination (Petousis-Harris, p 1875). We conclude with a commentary on postexposure rabies prophylaxis (Gozdas, p 1881).

Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss (adam.c.weiss@taylorandfrancis.com) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!

Sincerely,

Ronald Ellis, PhD

Editor-in-Chief

Adam Weiss

Acquisitions Editor


Articles from Human Vaccines & Immunotherapeutics are provided here courtesy of Taylor & Francis